EGFR-TKIs在晚期非小细胞肺癌靶向治疗中的临床研究  

Clinical Research of EGFR-TKIs in the Treatment of Patients with Advanced Non-small Cell Lung Cancer

作　　者：姜北[1] 李晶[1] 万鹏[1] 巩平[2] 

机构地区：[1]石河子大学医学院,新疆石河子832000 [2]石河子大学医学院第一附属医院,新疆石河子832000

出　　处：《现代生物医学进展》2013年第8期1489-1492,共4页Progress in Modern Biomedicine

基　　金：石河子大学医学院第一附属医院院级课题项目(YL2011-R017)

摘　　要：目的：探讨EGFR-TKIs在晚期非小细胞肺癌靶向治疗中的疗效及预后。方法：收集本院2009年~2011年经病理学或细胞学确诊的非小细胞肺癌患者92例,患者自愿口服EGFR-TKIs靶向治疗,直至疾病进展或发生不可耐受的药物毒副反应。服药4周后行客观疗效及毒副反应评估。入组患者均既往接受含铂类方案2-9周期化疗,平均4周期;全组患者随访时间均大于6个月。结果：92例患者均可评估疗效,CR为0%,PR为41.30%,SD为21.74%,PD为36.96%,客观有效率为41.30%,疾病控制率为63.04%。中位生存期12个月,1年生存率为42.39%。不良反应主要为皮疹和腹泻,其中三例发生III度痤疮样皮疹对症治疗不佳而停药,一例因发生III度间质性肺纤维化而停药,余总体耐受性良好。结论：EGFR-TKIs治疗晚期非小细胞肺癌患者可使其生存受益,并明显改善患者症状,且不良反应轻,耐受性良好。女性、腺癌及不吸烟患者接受EGFR-TKIs治疗可获得较好的临床获益率,疗效与选择厄洛替尼或吉非替尼无关。Objective： To observe the clinical efficacy and prognosis of EGFR-TKIs in the treatment of advanced non-small cell lung cancer. Methods： Collected 92 patients of non-small cell lung cancer who diagnosed by pathology or cytology from 2009 to 2011. The treatment of EGFR-TKIs were voluntarily accepted up to the disease progressed or toxicity reaction that cannot be tolerated to happen. Assessed the effect and toxicity reaction at 4 weeks after the use of EGFR-TKIs. All patients had accepted 2-9 cycles （4 cycles averaged） of platinum based chemotherapy. The whole group of patients were followed up for larger than 6 months. Results： All of 92 patients were evaluable. The complete response was 0 %, partial response rate was 41.30 %, 21.74 % of patients had stable disease, and 36.96 % patients had progressive disease. Hence, the disease control rate is 63.04 %. The median overall survival time （OS） was 12 months and the 1-year survival rate was 42.39 %. Rash and diarrhea is primary toxicity reaction. Four patients stopped taking the medication for 3 cases of III degree skin rash that treatment useless and 1 case of IIl degree interstitial pulmonary fibrosis. The rest was well tolerated. Conclusion： EGFR-TKIs treatment of advanced non-small cell lung cancer can make its survival benefit, and improve the symptoms of patients significantly. The toxicities are mild and tolerable. Women, gland cancer patients and no smoking can achieve a good clinical benefit on EGFR-TKIs treatment. The difference of the treatment of EGFR-TKIs have nothing to do with the choose of Erlotinib or Gefitinib.

关 键 词：EGFR-TKIS 晚期非小细胞肺癌 靶向治疗 疗效 

分 类 号：R-734[医药卫生]